Project Description

Your CRO of choice for neurology

NEUROLOGY

Despite the enormous steps that have been taken towards better understanding of central nervous system (CNS) diseases, healthcare systems worldwide face an unprecedented challenge in dealing with the unmet needs associated with neurological disorders. CNS diseases, and mental health disorders in particular, are one of the major health challenges of the 21st century, especially in light of an aging population (Race et al., 2013).

SCOPE International’s CNS/neurology team is here to help your clinical development program flourish with innovative recruitment strategies, strong site networks and local standard of care knowledge across an array of neurological disorder conditions. Our dedicated CNS project managers combine best practice and up-to-date knowledge of the relevant rating instruments in neurologic and psychiatric study development, in addition to strong local and global regulatory insight.

SCOPE International’s team has conducted a variety of CNS studies across diverse major aetiologies. With a full range of services and profound experience, we can define a strong development plan for your drug, device, or combination product and oversee the study from conception to delivery of the final report. We have successfully conducted more than 26 studies in neurology involving more than 1,000 clinical sites and 6,500 patients in both adult and paediatric indications. SCOPE International has established networks of investigators across different CNS indications; by maintaining close relationships with neurologists, psychiatrists, pain/palliative specialists and key opinion leaders.

We are able to provide rapid and accurate feasibility estimates at outset. We build upon our long-term relations with experienced, qualified and motivated sites to deliver your trial. From identifying the best sites, recruiting the right patients, to assuring assessments are properly completed by trained personnel, SCOPE can meet challenges and targets across a wide range of study designs and hard to recruit indications in CNS. Your program will be monitored by experienced clinical research associates, project managers, medical monitors and scientists who are familiar with the specific nuances, pitfalls and opportunities in these types of studies.
_

EXPERIENCE IN NEUROLOGICAL INDICATIONS

  • Epilepsy (including paediatrics)

  • Alzheimer ́s

  • Parkinson’s Disease

  • Sensorineural Disorders

  • Bipolar Disorder

  • Multiple Sclerosis

  • Mania

  • Narcolepsy

  • Depression

0
CNS STUDIES
0
SITES
0
SUBJECTS

OUR SPECIALISTS

contact us

DOWNLOAD

PRIMARY ENDPOINTS AND
PATIENT CENTRICITY

As CNS trials are highly reliant upon subjective endpoints, the choice of suitable psychometric instruments is essential to demonstrate efficacy. Our staff can advise in the selection of appropriate, well-defined and guideline-conforming tools appropriate for the use in clinical trials. These measures and their changes over time are coupled with support in standardisation and rater-trainings to ensure consistency and evaluable data. Most trial patients find it cumbersome to record health-related information using paper diaries, especially when the instruments require observer information. Therefore, technology driven data collection models for patient data collection, including handheld devices such as tablets, smartphone apps downloaded on patients’ phones, and electronic Patient Reported Outcome (e-PRO) instruments are a major consideration for a successful study set-up, and reduce the burden for patients. SCOPE works with selected providers for electronic Clinical Outcome Assessments (eCOA). Our monitors assist study coordinators in training patients to complete self-rated scales, ensuring timely capture and review of responses captured through patient diary data. Our trained project managers identify and mitigate study risks from the outset, while our site communications continually focus upon training, assessment, and feedback to ensure quality and consistency across all participating centers.